(firstQuint)Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies.

 This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.

 Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).

.

 Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies@highlight

The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.

